Trials / Completed
CompletedNCT05028582
Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)
A Randomized tRial Employing topiCal roflumilasT Foam to Treat Scalp Psoriasis (ARRECTOR)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 432 (actual)
- Sponsor
- Arcutis Biotherapeutics, Inc. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This was a parallel group, double blind, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-154) 0.3% foam vs vehicle foam applied once daily (qd) for 8 weeks by participants with plaque psoriasis of the scalp and body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Roflumilast Foam 0.3% | Roflumilast foam 0.3% |
| DRUG | Vehicle Foam | Vehicle foam matched to roflumilast 0.3% foam. |
Timeline
- Start date
- 2021-08-24
- Primary completion
- 2022-06-03
- Completion
- 2022-06-03
- First posted
- 2021-08-31
- Last updated
- 2025-07-17
- Results posted
- 2025-07-17
Locations
49 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05028582. Inclusion in this directory is not an endorsement.